



VCR PARK[®]
Harmonizing Innovation

VCR Fellowship in Molecular Pathology & Precision Oncology (VCR-MPPO)

Table of contents

| | |
|--|----|
| Overview | 2 |
| Track 1, Track 2 | 2 |
| Course highlights & Eligibility | 2 |
| Facilities | 3 |
| Syllabus | 4 |
| Projects | 6 |
| Fees | 6 |
| Future & future affiliation | 6 |
| Faculty: Clinical research & clinical trials | 7 |
| Faculty: Translational oncology | 11 |
| Faculty: Genetics & molecular biology | 13 |
| Faculty: Molecular pathology | 13 |
| How to apply | 14 |

HIGHLIGHTS AND PROSPECTS



VCR is the only comprehensive clinical, advanced pathology, and translational research lab in India



Stellar Indian and US faculty



Combined program between VCR, QNRI, and Emory (future)



Prospects:

- Immediate placement
- Leadership position in industry
- Conducting cutting edge clinical trials
- Working with the best oncologists
- Exposure to global training



Fees including accommodation and one-time food





VCR PARK
Harmonizing Innovation

VCR Fellowship in Molecular Pathology & Precision Oncology (VCR-MPPO)

Program Adviser:

**Dr. Ravi Nayar, MS (Chandigarh),
FRCS (Glasgow), DCCO (Paris), DLO
(London)**

Program Manager:

**Mr. Sravan Kumar P, MSc
Senior R&D & Training Manager**

VCR Park presents an exciting opportunity to enroll in the **first and only** advanced fellowship programs in the India for:

Track 1

Molecular Pathology

Beyond routine pathology and regular clinical practice, become a highly skilled advanced molecular pathologist with fundamental knowledge of clinical trial methodology. Obtain hands on experience with basic and advanced pathology, molecular and genomic techniques such as IHC, FISH, RT-PCR, Flow Cytometry, Sequencing, NGS. Participants will be trained over a 6 month period at our comprehensive research core lab in tandem with the practical interpretation of reports and application in the context of patient care at the clinical institute. Apply these skills to participate in a research project. Learn the principals of clinical research conduct, ethics and the regulation of companion diagnostics.

Track 2

Precision Oncology

Trainees will receive comprehensive knowledge of the principals of genetics and its application towards precision medicine. Learn about the latest advances in targeted oncology therapies. Fundamental knowledge of basic and advanced clinical trial methodology with a focus on early phase clinical trial design, ethics and regulatory requirements. You will be able to participate in a translational research project and an ongoing clinical trial. Benefit from hands-on exposure to the basics of molecular methodologies such as PCT, RT-PCR, IHC, FISH, and NGS.

Course Highlights

- Duration: **6 Months**
- No of positions:
 - Track 1: 2
 - Track 2: 2

Eligibility

- MBBS with MD or DNB
- Pathology (Track 1 or 2) or General medicine specialists preferred (Track 2)
- Degree recognized by MCI



Facilities



- ❑ Comprehensive multi-speciality tertiary care hospital
- ❑ Treats >6000 cancer patients annually
- ❑ Oncology facility with radiation, surgical, & medical departments



- ❑ Integrated state-of-the-art lab facility for translational oncology research recognized by Department of Biotechnology, India. A designated center of excellence under the BioNest program with the following cores:
- ❑ Advanced pathology
- ❑ Molecular and genomics core
- ❑ Proteomics core

| Cell Biology | Genomics |
|---|---|
| Invitrogen: EVOS™ FL Auto Imaging System* | Illumina: NextSeq 2000* |
| Invitrogen: Countess™ II FL Automated Cell Counter* | Proteomics and Metabolomics (SCIEX CoE)* |
| Molecular Devices: ImageXpress Micro Confocal HCS* | SCIEX: QTRAP 6500+ System |
| Molecular Biology | SCIEX: TripleTOF 6600+ System |
| Invitrogen: QuantStudio 5 Real-Time PCR System* | SCIEX: Ekspert nanoLC 425 and Eksigent M5 microLC |
| Invitrogen: iBright FL1000 Imaging Systems* | Peak: Genius 1024 tri gas generator |
| Perkin Elmer: VICTOR Nivo Multimode Microplate Reader* | Analytical and Protein Chemistry |
| Advanced Pathology | Cytiva: AKTA Avant 150 FPLC* |
| Ventana: BenchMark ULTRA Discovery IHC/ISH system* | Waters: 1525 analytical and semipreparative LC* |
| Beckman Coulter: CytoFLEX LX Flow Cytometer* | |

+ VCR, * BioNEST, ~ ABSciex


Syllabus

The course designed to train clinicians across the following competencies. The extent of training in these areas will be determined by the track.

i) Genetics and Precision Oncology:


Lectures by
esteemed clinical
faculty



Rotational exposure
to oncology patients
at Queens NRI
hospital

ii) Advanced Molecular Pathology:


Interactive
review



Lectures to understand
the platforms



Clinical interpretation
and assay
development




Hand-on training
using
clinical samples for



PCR, RT-PCR, Sanger
sequencing,
Immunohistochemistry,
Fluorescence in situ
Hybridization, Flow Cytometry,
and NGS



iii) Translational Oncology



Understanding the translational process and clinical application

iv) Clinical Trials



Fellows will design a clinical study under faculty guidance

Training will include

- Design and data analysis
- Ethics
- Merits and demerits of departures from conventional randomization
- Complex clinical trials and statistics

Projects

- Translational oncology project at VCR Park
- Dedicating time to ongoing projects
- Project assignments at the end of the 2nd week



Fees

- The total cost of the course is Rs 4,00,000 including accommodation and one meal per day

Future

- Immediate placement at VCR Park with a minimum salary of 24 LPA
- Become distinguished leaders in industry
- Create a unique skill profile as a combination of clinical, translational, molecular pathology, regulatory, and clinical trials skills
- Lead the transformation of clinical trials in India and contribute to improving cancer care

Future Affiliation

- Emory University, Atlanta, USA
- Exchange program and training by faculty at Emory may be possible



Faculty

Clinical Research & Clinical Trials



Dr. Govind Babu, MD, DM
Consultant, Medical oncology,
HCG, Bengaluru, KA, INDIA

Dr K. Govind Babu completed his post-graduation in Internal Medicine and holds super specialty in Medical Oncology, from prestigious Institutes in Bangalore, Karnataka. He has received training at the Dana Farber and MD Anderson centre in the USA. Dr Babu has over 60 national and international publications to his credit. He is a recipient of many national and international awards and has been a part of many national and international researches, including clinical trials in oncology. Dr Babu's key areas of expertise are solid tumors and hemato-oncology and he is keenly involved in targeted therapies and precision medicine.



Dr. Raghunadha Rao, MD, DM
Director, Homi Bhabha Cancer
Hospital & Research Centre,
Visakhapatnam, AP, INDIA

Dr. Raghunadharao is the Director of Homi Bhabha Cancer Hospital and Research Center and a member of International Chronic Myeloid Leukaemia Foundation and Indian Cooperative Oncology Network. Besides being the first medical oncologist of (united) Andhra Pradesh, Dr. Rao had many firsts to his credit; including establishing the first Medical Oncology department and a comprehensive cancer care centre in 1989, setting up a clinical research facility in 1992, starting a DM Medical Oncology Course in 2005; and establishing the first population-based Cancer Registry in 2012 in Andhra Pradesh at Nizam's Institute of Medical Sciences. He has >20yrs of experience in the field of medical oncology where he served as a clinical research physician and professor in NIMS. He has conducted over 100 clinical trials in India and is considered a pioneer of cancer clinical trials in India.



**Dr. Ravi Nayar, MS, DNBE,
DCCF Paris, DLO, FRCS**
Dean Academics, HCG,
Bengaluru, KA, INDIA

Dr. Ravi Nayar is the Dean, Center for academic research in oncology and consultant otolaryngologist at Health Care Global Enterprises (HCG). He is the president of the Bangalore Branch of the ENT association of India. He is the Professor and Head of Department for Head and Neck Surgery at St. Johns Medical College, Bangalore and an Honorary Visiting Professor at PES engineering college



**Dr. Kumar Prabhash, MBBS,
DM**
Head, Tata Memorial Hospital,
Mumbai, MH, INDIA

Dr. Kumar is a professor and medical oncologist in Tata Memorial Hospital and has more than two decades of experience. He is the present President and convener of Indian Cooperative Oncology Network (ICON). He has so far published over a hundred research and review articles/papers in journals of national and international repute and had undertaken over 80 projects as Principal Investigator and Co-Investigator. He is a member of many international and national scientific societies and associations and has delivered talks in several conferences. These days he is proactive in increasing awareness about lung cancer and has successfully conceptualized Lung Cancer Consortium Asia.



Dr. Sewanti Limaye, MD, MS
 Consultant & Surgeon, Kokilaben
 Dhirubhai Ambani Hospital,
 Mumbai, MH, India

Dr. Sewanti is a Consultant & Surgeon at Kokilaben Dhirubhai Ambani Hospital. She specializes in the treatment of all Solid Tumors. She has specific expertise in Cancer Genomics, Targeted Therapy and cutting-edge treatment with Immunotherapy. She is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Limaye received her medical degree with honors from Jawahar Lal Nehru Medical College, Bhagalpur and did her residency in Internal Medicine from New York University. She did her fellowship in Hematology and Medical Oncology from Albert Einstein University, North Shore- Long Island Jewish Medical Center, New York. She conducted research at Memorial Sloan Kettering Cancer Center, Dana Farber Cancer Institute, Columbia University Medical Center and National Cancer Institute, USA. She has led several national and international trials and has been a part of Data Safety Monitoring Boards.



**Dr. Himabindu Gaddipati,
 MD, EMTM**
 CEO and Founder, Lumiseek Inc.
 San Diego, CA, USA
 Chairman and MD, VCR Park
 Visakhapatnam, AP, INDIA

Dr. Himabindu Gaddipati is a practicing Oncologist in San Diego, CA. After graduating from Andhra Medical College, Visakhapatnam in 1999 she pursued 8 years of post-graduate training at University of Virginia in the United States. She completed Internal Medicine residency followed by post-doc fellowships in Genetics and Molecular Biology from the University of Pennsylvania, PA and Hematology/Oncology from University Hospitals/Case Western Reserve University. She served as a visiting scientist at the Wistar Research Institute. She was subsequently trained as an Interagency Taskforce Oncology Product Development post-doc fellow at the National Cancer Institute, Bethesda and FDA. At the NCI, she served as an analyst for the Federal Small Business Innovation Research (SBIR Program) and also completed a certificate program in Technology Transfer. She completed Executive Master's in Technology Management (EMTM) from Wharton School of Business. She is currently the co-chair for the Biocom oncology group, a network of more than 120 organizations including hospitals, research institutions, companies and foundations engaged in cancer related activities in the Southern California.

Translational Oncology**Dr. Kishor Bhatia, PhD**

Senior Consultant,
Lantern Pharma, Dallas,
TX, USA

Dr. Bhatia holds a PhD from University of Mumbai and is Fellow of the Royal College of Pathology UK. He was a tenured scientist at NCI and helped lead research to understand the pathogenesis and epidemiology of Burkitt's lymphomas. Subsequently he was the Director of the Children's Cancer Research Center of King Faisal Hospital in Riyadh and Director of the AIDS Malignancy Program at the NCI. He has also worked as a member of the governing board of the International Network for Cancer Treatment Research in Brussels. Dr. Bhatia has published over 150 peer-reviewed papers in international journals and is also currently an adjunct investigator with the NCI.

**Dr. Purvsih Parikh, MD**

Director, Precision
Oncology and Research,
Asian Institute of
Oncology, Somaiya
Ayurvihar: Cancer Care,
Mumbai, MH INDIA

Dr. Parikh is the President of Molecular Oncology Society, Director of Precision Oncology and Research at Asian Institute of Oncology at Somaiya Ayurvihar Cancer Care, he serves as editor of South Asian Journal of Cancer and Indian Journal of Cancer as well. He is a certified physician investigator of AAPI and ACRP. He served as Professor and Chief of Medical Oncology at Tata Memorial Hospital for 17 years, as well as Founder and Director of a nongovernmental organization, the Indian Co-operative Oncology Network. Dr. Parikh received a M.D. from Bombay University, and earned both a Ph.D. and an M.B.A. from the University of Mumbai."



Dr. Mandar Kulkarni, PhD
CEO, VCR Park
Visakhapatnam, AP, INDIA
VP, Lumiseek,
San Diego, CA, USA

After earning his doctorate in molecular carcinogenesis from Purdue University, Dr. Kulkarni was selected to become a T32 fellow at the Yale School of Medicine and was awarded a young scientist award for his work in the structural biology and signal transduction. As a senior scientist at M/Z Diagnostics, he managed business, obtained an NIH-SBIR grant as a PI, and was awarded a Young scientist award by the FSG. At Sandor Lifesciences, as the Head of Molecular Biology and Genomics, he designed and executed numerous NGS, microarray and bioinformatics projects. Then, as the Chief Technology Officer at CGIndia, he managed all operations and lead the development of research services, diagnostics, biopharma services, R&D, and genomics-based clinical assays in the area of precision oncology. He was also responsible for ensuring the financial success of the Indian business unit and established several high value collaborations in the Indian personalized oncology space.



Dr. Prashant Kumar, PhD
Ramanujan Fellow, Institute of
Bioinformatics, Bengaluru, KA,
INDIA

Dr. Prashant Kumar is a faculty scientist at Institute of Bioinformatics centered on biomarker discovery for bladder cancers, using state-of-the-art quantitative proteomics approaches. The major focus of current research in his laboratory is to optimize circulating tumor cells (CTCs) culture conditions, for individualized testing of drug susceptibility. Prior to IOB, he worked as Research Scientist at Institute of Molecular and Cell Biology (IMCB) at Singapore.

Genetics & Molecular Biology



Prof. Narendra Naidu, M. Phil

Head, Department of Zoology
Modern College
Pune, MH, India

Professor Naidu completed his M. Phil. In developmental biology at the University of Pune and joined the Modern College as a professor. He has taught all undergraduate and graduate courses in the department of Zoology and Entomology. He has over 30 years of teaching experience and currently is the Head of the Department of Zoology. He has an unconventional approach to teaching and an instinct to connect with each student. He has also been the president of the CHYK chapter and involved in several social causes.

Molecular Pathology



Dr. Payal Keswarpu, MBBS, MD

Director, Westchester
KnowledgeWorks, Bengaluru, KA,
India

Dr. Keswarpu possesses over 20 years of professional health science experience and her track record is unparalleled. As a Physician Scientist passionate about translational medicine, she has also held numerous leadership positions and has driven product innovations in healthcare while utilizing her clinical knowledge of pathology and oncology. Dr. Keswarpu has been granted multiple patents and has published scientific articles in many journals. She is also the recipient of major awards and honors for her work in academic settings and during her engagements in corporate roles.



How to apply

Send an application packet of following material in the indicated order in pdf format to fellowship@vcrpark.com

- 1-page resume
- Statement of purpose
- Summary of clinical experience
- 1 letter of recommendation
- Copy of medical degree(s)



Contact

**VCR Park,
Anchorage, Plot No. 9&12, Krishna Nagar,
Maharani Peta, Visakhapatnam, AP 530002. INDIA
+91 0891 2588502
info@vcrpark.com || www.vcrpark.com**